{"id":1768,"date":"2010-05-01T12:02:00","date_gmt":"2010-05-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln"},"modified":"2022-03-17T14:11:50","modified_gmt":"2022-03-17T13:11:50","slug":"accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln","title":{"rendered":"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln"},"content":{"rendered":"<p>\u00dcber die Ergebnisse der ACCORD-Studie bei Patienten mit unterschiedlich strenger Blutzuckereinstellung bei Diabetes mellitus Typ 2 (DM2) haben wir 2008 berichtet (1, 2). Die Studie wurde nach einer medianen Beobachtungsdauer von 3,4 Jahren vorzeitig beendet, da die Sterblichkeit der intensiver behandelten Patienten (Ziel-HbA1c: < 6%) gegen\u00fcber der Standardbehandlung (Ziel-HbA1c: 7-7,9%) signifikant h\u00f6her war. ACCORD ist [&hellip;]\n<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00dcber die Ergebnisse der ACCORD-Studie bei Patienten mit unterschiedlich strenger Blutzuckereinstellung bei Diabetes mellitus Typ 2 (DM2) haben wir 2008 berichtet (1, 2). Die Studie wurde nach einer medianen Beobachtungsdauer von 3,4 Jahren vorzeitig beendet, da die Sterblichkeit der intensiver behandelten Patienten (Ziel-HbA1c: < 6%) gegen\u00fcber der Standardbehandlung (Ziel-HbA1c: 7-7,9%) signifikant h\u00f6her war. ACCORD ist [&hellip;]\n<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3949,438,60,324,451,449,155,2625,71,68,455,453,325,498,456,65,56,505,443],"class_list":["post-1768","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-accord-lipid-studie","tag-antihypertensiva","tag-apoplektischer-insult","tag-blutdruck","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-diabetes-mellitus-typ-2","tag-fenofibrat","tag-herzinfarkt","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-hypertonie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-schlaganfall","tag-simvastatin","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1768"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1768\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}